Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial

Biomarkers with prognostic and predictive value can help stratify patients with colorectal cancer (CRC) into appropriate treatment groups. We sought to evaluate the clinical utility of P53 protein expression as a biomarker in VICTOR, a large phase III trial of rofecoxib in stage II and III CRC. Tiss...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2015-03, Vol.35 (3), p.1641-1645
Main Authors: McGregor, Megan J, Fadhil, Wakkas, Wharton, Rose, Yanagisawa, Yoko, Presz, Michael, Pritchard, Alison, Womack, Chris, Dutton, Susan, Kerr, Rachel S, Kerr, David J, Johnstone, Elaine C, Ilyas, Mohammad
Format: Article
Language:English
Subjects:
Biomarkers
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Genes, p53
Humans
Immunohistochemistry
Lactones - therapeutic use
Mutation
Neoplasm Staging
Prognosis
Sulfones - therapeutic use
Tumor Suppressor Protein p53 - analysis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biomarkers with prognostic and predictive value can help stratify patients with colorectal cancer (CRC) into appropriate treatment groups. We sought to evaluate the clinical utility of P53 protein expression as a biomarker in VICTOR, a large phase III trial of rofecoxib in stage II and III CRC. Tissue micro arrays were constructed from 884 tumors and the expression of P53 was examined by immunohistochemistry. Tumors were dichotomised as either P53-positive (nuclear expression in >10% of cells or the 'absent' pattern, both representing TP53 mutation) or P53-negative (nuclear expression in
ISSN:0250-7005
1791-7530